1355a4eb_nter___Yale_School_of_Medicine__Conditions
[Study Title] A Phase I/II, Dose-escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varlilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (CDX1127-02) [Conditions] 
Melanoma, skin
M e l a n o m a , s k i n
S o f t T i s s u e
Mario Sznol, MD > Yale Cancer Center | Yale School of Medicine
Conditions